Tabelle 3B.
Results for FOLFIRI plus bevacizumab treated patients (n=168)
| SNP | Genotype (N) | ORR (%) | p* | PFS months | p** | HR | OS months | p** | HR |
|---|---|---|---|---|---|---|---|---|---|
| rs895374 | CC (65) | 71.7 | 0.17 | 10.5 | 0.84 | 25.4 | 0.82 | ||
| AC (79) | 59.2 | 12.5 | 0.90 | 28.6 | 0.88 | ||||
| AA (24) | 76.7 | 10.8 | 0.91 | 25.0 | 0.88 | ||||
| rs379464 | CC (6) | 80.0 | 0.79 | 6.9 | 0.16 | 13.0 | 0.18 | ||
| CT (45) | 65.0 | 14.5 | 1.7 | 26.1 | 1.57 | ||||
| TT (86) | 67.1 | 18.0 | 1.4 | 28.9 | 1.49 | ||||
| rs7051590 | CC (96) | 67.4 | 0.73 | 11.3 | 0.65 | 25.9 | 0.11 | ||
| CG (9) | 77.8 | 14.9 | 1.1 | nr | 0.85 | ||||
| GG (21) | 73.7 | 9.8 | 0.77 | 30.8 | 0.22 | ||||
| rs2511837 | CC (47) | 65.9 | 0.90 | 11.3 | 0.41 | 29.1 | 0.72 | ||
| CT (48) | 69.0 | 12.4 | 0.87 | 24.9 | 1.06 | ||||
| TT (45) | 64.3 | 10.2 | 0.47 | 27.5 | 1.23 | ||||
| rs17567 | CC (6) | 50.0 | 0.03 | 12.8 | 0.36 | 27.7 | 0.73 | ||
| CT (48) | 55.8 | 9.8 | 0.91 | 25.0 | 0.70 | ||||
| TT (86) | 77.2 | 11.5 | 1.3 | 28.1 | 1.1 | ||||
Legend: ORR = objective response rate; PFS = progression-free survival, OS = overall survival, 95% HR= Hazard ratio
*
p= CHI-square test p
**
p= logrank test p, A= adenine, C= cytosine, G= guanine, T= thymidine, nr = not reached